#evidence

Peter Attia lays out a five-question framework (mechanism, human evidence, safety/dosing, risk-benefit, better-characterized alternatives) for evaluating any peptide, then applies it to BPC-157 and CJC-1295 to show why gray-market peptide claims tend to expand over time instead of narrowing, unlike legitimate drug development.

via #403 ‒ Peptides: separating scientific promise from marketing hype